SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 199.53+1.5%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (10992)11/12/1997 2:41:00 AM
From: squetch  Read Replies (1) of 32384
 
Here is some info from a Rezulin ad I saw. This is from the fine print part and I don't know if this "caution" section was pre or post FDA letter.

During all clinical studies in NorthAmer (n=2510) a total of 20 Rez-treated patients were withdrawn for treatment b/c of liver fx test abnormalities. 2/20 developed reversible jaundice. Both had biopsies which were consistent w/ idiosyncratic drug reaction.

In premenopousal anormulatroy patients w/ insulin resistance, Rez may result in resumption of ovulation.

hemogloblin decreased 3-4% compared w/ a 1-2% decrease in placebo. Change occured in first 4-8 weeks. Levels stabilized and remained unchanged(up to two years in my recollection is correct Yes a big IF)

Risk of hypoglycemia if used in combo w/ insulin or oral hypoglycemic agents

Recomend insulin not Rez during pregnancy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext